- Home
- CBNA vs GNLX Comparison
CBNA vs GNLX Comparison
Compare CBNA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- GNLX
- Stock Information
- Founded
- CBNA 2006
- GNLX 2001
- Country
- CBNA United States
- GNLX United States
- Employees
- CBNA N/A
- GNLX N/A
- Industry
- CBNA
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- GNLX Health Care
- Exchange
- CBNA NYSE
- GNLX Nasdaq
- Market Cap
- CBNA 133.2M
- GNLX 103.6M
- IPO Year
- CBNA 2024
- GNLX 2023
- Fundamental
- Price
- CBNA $24.40
- GNLX $2.69
- Analyst Decision
- CBNA Buy
- GNLX Strong Buy
- Analyst Count
- CBNA 3
- GNLX 4
- Target Price
- CBNA $27.67
- GNLX $18.25
- AVG Volume (30 Days)
- CBNA 38.9K
- GNLX 178.7K
- Earning Date
- CBNA 10-29-2024
- GNLX 11-14-2024
- Dividend Yield
- CBNA N/A
- GNLX N/A
- EPS Growth
- CBNA 131.15
- GNLX N/A
- EPS
- CBNA 749.51
- GNLX N/A
- Revenue
- CBNA $49,968,000.00
- GNLX $8,000.00
- Revenue This Year
- CBNA N/A
- GNLX N/A
- Revenue Next Year
- CBNA N/A
- GNLX N/A
- P/E Ratio
- CBNA $0.03
- GNLX N/A
- Revenue Growth
- CBNA 76.01
- GNLX N/A
- 52 Week Low
- CBNA $20.10
- GNLX $1.60
- 52 Week High
- CBNA $25.00
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- GNLX 49.88
- Support Level
- CBNA N/A
- GNLX $2.48
- Resistance Level
- CBNA N/A
- GNLX $2.78
- Average True Range (ATR)
- CBNA 0.00
- GNLX 0.26
- MACD
- CBNA 0.00
- GNLX -0.02
- Stochastic Oscillator
- CBNA 0.00
- GNLX 48.65
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.